Business
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
- Lead clinical program of onvansertib in KRAS-mutated metastatic colorectal cancer continues to generate data showing robust response to treatment and
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"- Lead clinical program of onvansertib in KRAS-mutated metastatic colorectal cancer continues to generate data showing robust response to treatment and progression-free survival\n - First patient dosed in Phase 2 study of onvansertib in combination with standard-of-care for the treatment of metastatic pancreatic ductal adenocarcinoma\n - Newly appointed CMO and CFO, and shareholders elected two new members to Company's Board of Directors, with expertise in drug development, financial strategy, and business development\n\n\nSAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced recent company highlights and financial results for the second quarter ended June 30, 2021. \n\n \n \n \n \n \n \n\n \n\"During the past few months, we have achieved important clinical milestones that have advanced our drug development programs and further highlighted the clinical benefits of onvansertib across indications representing some of the most difficult to treat cancers\" said Mark Erlander, Ph.D., chief executive officer of Cardiff Oncology. \"The added expertise in drug development, financial strategy and business development brought by our CMO, CFO and new board members comes at a pivotal time for the Company, as our strong cash position and recent progress in our clinical and preclinical programs has us poised for a steady cadence of catalysts over the coming months.\"\nDr. Erlander continued, \"Our clinical progress during the second quarter was highlighted by advancements in our two KRAS-focused programs. In metastatic pancreatic ductal adenocarcinoma (mPDAC), where approximately 95% of patients have a KRAS mutation, we began dosing patients in our Phase 2 trial evaluating onvansertib in combination with nanoliposomal irinotecan, 5-FU and leucovorin. This trial is supported by the promising data from our lead KRAS-mutated metastatic colorectal cancer program presented in April, which showed that treatment with onvansertib plus irinotecan, 5-FU and bevacizumab resulted in an overall response rate and median progression free survival that compare fa...